INTRODUCTION
Ptdlns 4-kinase is the first enzyme in a pathway by which a lipid component of cellular membranes is converted to PtdIns(4,5)P2, the immediate precursor of the second messengers Ins(1,4,5)P3 and diacylglycerol. Although it would seem likely that regulation of this enzyme is important in determining the magnitude of the second messenger response to agonists, little is known about such regulation. Ptdlns 4-kinases are membraneassociated enzymes which have been described in many tissues and species, and have been purified from A431 cells [1] , bovine uterus [2] , rat brain [3] , pig liver [4] , bovine brain myelin [5] and yeast [6] .
We have previously shown that two types of Ptdlns kinase can be separated from detergent extracts of bovine brain membranes by rate zonal centrifugation on sucrose gradients [7] . We found that 43 % of the total Ptdlns kinase activity, termed brain type II, migrated on the gradients with an approximate size of 55 kDa, similar to the bovine uterus and A43 1 cell enzymes. The brain type II, bovine uterus and A431 cell activities also possess similar Km values for ATP and Ptdlns [1, 2, 7] . The remainder of the brain membrane activity, termed brain type III, migrates on sucrose gradients with an approximate size of 230 kDa. This activity shares certain properties with a Ptdlns kinase purified from rat brain, including similar Km values for Ptdlns and poor inhibition by adenosine [3, 7] . A Ptdlns 4-kinase activity with similar characteristics has also been described in bovine uterus [8] .
The products of the Ptdlns kinase activities described above have been either demonstrated or presumed to be PtdIns4P. A PtdIns 3-kinase activity has been described which specifically associates with activated tyrosine kinases. The function of this activity, previously called type I Ptdlns kinase, is unknown [9] .
In order to be able to functionally distinguish these various Ptdlns kinase activities in vivo, we have developed a monoclonal antibody which inhibits the type II, but not the type III, PtdIns 4-kinase activity from bovine brain membranes. This antibody inhibits PtdIns 4-kinase activities from other species and tissues, but does not inhibit Ptdlns 3-kinase.
MATERIALS AND METHODS Materials
Azaserine, hypoxanthine, penicillin and streptomycin were purchased from Sigma. [y-32P]ATP (3000 Ci/mmol) was from Amersham, poly(ethylene glycol) from ATCC, RPMI-1640 medium and fetal bovine serum from Hyclone, and glutamine and pyruvate from Gibco. Other materials were from the sources previously described [7] .
Assay of brain Ptdlns kinase activities
Ptdlns 4-kinase activities were assayed by measuring the incorporation of label from [y-32P]ATP into PtdlnsP in the presence of 0.1 % Triton X-100 exactly as described [7] . The radioactive reaction product was isolated by t.l.c. and located by autoradiography. Types II and III Ptdlns kinase were fractionated from a detergent extract of bovine or rat brain membranes by centrifugation on sucrose density gradients [7] . The product of both types II and III PtdIns kinase from brain membranes has been shown to be PtdIns4P by comigration of deacylated material with glycerophosphoinositol 4-phosphate (G. Endemann, unpublished work).
Assay of rat liver cytosolic PtdIns kinase activities
Rat liver was homogenized in 2 vol. of 50 mM-Hepes (pH 7.8)/10 % (v/v) glycerol/l mM-vanadate/0. l mM-phenylmethanesulphonyl fluoride (PMSF)/leupeptin (I ,ug/ml)/ aprotinin (1 ,ug/ml). The homogenate was centrifuged at 9000 g for 20 min, and the resulting supernatant was centrifuged for I h at 120000 g to obtain cytosol and microsomal fractions. PtdIns kinase activities from rat liver cytosol were assayed with sonicated Ptdlns in the absence of detergent as described [10] . After isolation by t.l.c., the PtdInsP was deacylated and analysed by h.p.l.c. [9] in order to distinguish PtdIns3P and PtdIns4P.
Partial purification of type II Ptdlns kinase Bovine brain membranes were prepared as described [7] , and a soluble extract was made with 0.5% Triton 1 mM-dithiothreitol, 0.5 mM-ATP and proteinase/phosphatase inhibitors (1 mM-EDTA, 0.2 mM-ammonium vanadate, 0.2 mm-PMSF, 1 ,ug of soybean trypsin inhibitor/ml and 1 ,ug of aprotinin/ml)]. A 50 ml portion of the extract was run over a 500 ml column of DEAE-Sephacel in buffer A containing 1 % Triton X-100, and the flow-through fractions containing type II Ptdlns kinase [7] were pooled and dialysed against buffer B (25 mM-Mes, pH 6.0, 20 % (w/v) glycerol, 1 % Triton X-100, 5 mM-MgCl2, 0.1 mM-ATP, 1 mM-dithiothreitol and proteinase/phosphatase inhibitors). The preparation was loaded on to a 50 ml column of SP-Sephadex C-50 (Pharmacia), and proteins were eluted with a 0-0.3 M-NaCl gradient in buffer B. Fractions containing PtdIns kinase activity were dialysed against buffer B and loaded on to a 5 ml column of SP-Sephadex. The column was eluted with 0.5 M-NaCl in buffer B containing 0.1 % Triton X-100. The eluate was diluted to < 0.01 % Triton X-100 in buffer B containing 0.5 M-NaCl and mixed with 35 ml of phenyl-Sepharose (Pharmacia) equilibrated with the same buffer. After a 30 min incubation, the gel was washed with buffer B containing 0.5 M-NaCl and 0.01 % Triton X-100, and eluted with 6 x 60 ml portions of buffer B containing 0.5 % Triton X-100. The Ptdlns kinase activity was concentrated on a 1 ml column of SP-Sephadex and eluted with 0.5 M-NaCl/0.1 % Triton X-100.
Monoclonal antibody production and characterization
The SP-Sephadex eluate was concentrated and washed in a Centricon 30 (Amicon) to a final composition of 625 ,g of protein/ml in 0.25 % Triton X-100/0.15 M-NaCl/10 mM-Hepes (pH 7.1)/20 % glycerol/I mM-dithiothreitol/I mM-EDTA. An equal volume of Ribi adjuvant (Ribi Immunochemicals) was vortex-mixed with the Ptdlns kinase for I min. A 25 ,ul portion of this mixture was injected (using a Hamilton syringe with a 25G, pt 4 needle) into the rear footpads of 4-week-old Balb/C female mice (Charles River), once a week for 7 weeks.
Popliteal lymph nodes were the source of cells used for the production of antibody-producing hybridoma lines. Lymph node cells from one mouse were mixed with SP2/0-Agl4 myeloma cells [11] at a ratio of 2: 1, and suspended in 50 ,ul of phosphatebuffered saline (8.2 mM-Na2HPO4/1.5 mM-kH2PO4/138 mMNaCI). Fusion was carried out according to Galfre et al. [12] with the following modifications. A 1 ml portion of RPMI containing 400% poly(ethylene glycol) and 100% (v/v) dimethyl sulphoxide at 37°C was added with shaking over 30 s. After 2 min, 2 ml of 100% (v/v) dimethyl sulphoxide in RPMI was added dropwise with shaking over the next 2 min, followed by 7 ml over the next 3.5 min. Then 15 ml of RPMI was slowly added, and the cells were gently pelleted and resuspended in 1 ml of RPMI. Fusion medium [RPMI 1640/20 % (v/v) fetal bovine serum/penicillin/ streptomycin/2 mM-L-glutamine/ 1 mM-pyruvate/0. 1 mmhypoxanthine/azaserine (2 ,ug/ml)] and the cells from one mouse thymus (dissociated by rubbing gently between two ground glass slides) were added, and the suspension was plated in a 96-well plate.
Colonies from lymph node hybridomas were screened for production of anti-(Ptdlns kinase) antibodies in two ways. First, hybridoma supernatants were incubated for 4-15 h at 4°C with partially purified type II Ptdlns kinase before assay of PtdIns kinase activity, in order to detect inhibitory antibodies. Secondly, antibodies which could immunoprecipitate Ptdlns kinase activity were detected by the subsequent addition of goat anti-(mouse Ig)-Agarose (Hyclone) in immunoprecipitation buffer [50 mM-Tris (pH 8)/20 % glycerol/I mM-EDTA/1 0% Triton X-100/1 mM-dithiothreitol, 50 1sM-ATP/0.2 mM-PMSF/soybean trypsin inhibitor (1 ,ug/ml)/aprotinin (1 ,ug/ml)] to the hybridoma supernatant/Ptdlns kinase mixture. After 2 h at 4°C with mixing, the pellets were washed five times with buffer (the second and fourth washes contained 0.5 M-NaCl), and assayed for Ptdlns kinase activity. Colonies which were positive in either assay were cloned by limiting dilution. The subisotype of 4CSG was determined to be IgGI using a kit from Hyclone. The 4C5G hybridoma line was used to obtain ascitic fluid from mice primed with Freund's incomplete adjuvant. IgGI was purified from ascites fluid by binding to Protein A-Sepharose (Sigma) at pH 8.0, and eluting at pH 6.0 [13] . 4C5G was stored in 0.01 % NaN3 or at -80 'C.
RESULTS

Production of a monoclonal antibody, 4C5G, which recognizes type II Ptdlns 4-kinase
Type II Ptdlns 4-kinase was purified 686-fold from bovine brain membranes to a specific activity of 24 nmol/min per mg (Table 1 ). This material was used to immunize mice, and B cells producing antibody in response to this antigen were obtained from the popliteal lymph nodes. Hybridoma cell lines made from these B cells were screened for the production of antibodies which could either inhibit type II Ptdlns kinase activity or immunoprecipitate type II PtdIns kinase activity. Hybridomas which were positive in either assay were cloned by limiting dilution, and the same clone, 4CSG, was strongly positive in both assays. This apparent contradiction was explained on quantification of Ptdlns kinase activity in both the supernatant and the pellet following immunoprecipitation with 4CSG. Only a small fraction of the activity which is cleared from the supernatant is recovered in the pellet. Ptdlns Ptdlns kinase from a detergent extract of bovine brain membranes were separated by density-gradient centrifugation as described [7] . As shown in Fig. 1 the indicated levels of purified 4C5G, and PtdIns kinase activity was then measured in the absence of detergent. 0, Detergent-solubilized type II Ptdlns kinase from bovine brain was incubated with purified 4C5G, and PtdIns kinase activity was then measured in the standard assay with 0.1 % Triton X-100.
detergent micelles (Fig. 2) . 4C5G inhibited approx. 50 % of the PtdIns kinase activity in bovine brain membranes, the expected proportion of type II Ptdlns kinase [7] . it is unable to inhibit the cytosolic PtdIns 3-kinase activity, even at high concentrations (Fig. 3) . A rat liver microsomal Ptdlns 4-kinase activity, assayed in 0.1 % Triton X-100, is also inhibited by 4C5G (results not shown).
4C5G recognizes a domain common to Ptdlns 4-kinases from several species When a detergent extract of rat brain membranes is fractionated by sucrose-density-gradient centrifugation, types II and III Ptdlns 4-kinases are resolved, with mobilities exactly the same as those of the bovine enzymes. These activities are also distinguished by 4C5G as for bovine activities (Table 2 ). Both the human erythrocyte [7] and Xenopus laevis oocyte (results not shown) Ptdlns 4-kinases migrate on sucrose gradients as a single peak with the apparent size of the brain type II activity. These activities are inhibited to various degrees by 4C5G (Table 2) . [7] . The presence of an epitope recognized by 4C5G in the brain type II PtdIns 4-kinase, which is not accessible in the brain type III activity, lends further support to the existence of two distinct gene products. The conservation of the domain recognized by 4C5G across species, including human, cow, rat and Xenopus laevis, argues for the functional significance of this domain, and suggests that the absence of this domain in the type III enzyme reflects a significant difference in function or regulation.
Type II Ptdlns 4-kinase in intact native membranes is 90 % inhibited by 20 jug of 4C5G/ml; thus it will be possible to use 4C5G to study the involvement of this enzyme in the elevated metabolism of membrane polyphosphoinositides which occurs in response to various agonists. The presence of more than one type of Ptdlns 4-kinase in membranes raises several possibilities as to their functions. First, the two enzymes may be activated in response to different ligands, either through regulation by second messengers or by co-localization in membrane domains. Secondly, one of the PtdIns 4-kinases may participate in ligandstimulated polyphosphoinositide turnover, while the other is a housekeeping enzyme, necessary to maintain membrane PtdIns4P levels. Elucidation of the roles of the PtdIns kinases should facilitate the study of polyphosphoinositide metabolism in signal transduction pathways.
